Verification evidence is still being completed.
PDF / print export
SAGA Diagnostics
Lund, Sweden
- Verified lead
- Peter Collins
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Tumor-Informed Liquid Biopsy, Molecular Residual Disease Detection, and Cancer Monitoring
- Review cycle
- 24 April 2026
- Full address
- Medicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- PR Newswire release confirming Peter Collins as Chief Executive Officer of SAGA Diagnostics.
- Editorial note
- Lund-anchored liquid biopsy MRD specialist with a named CEO, CLIA-certified US laboratory, commercial Pathlight Breast MRD test, and a disclosed 2026 Roche acquisition agreement worth up to 595 million USD.
Tumor-Informed Liquid Biopsy, Molecular Residual Disease Detection, and Cancer Monitoring
CLIA certification of the RTP laboratory, Public leadership disclosure, Documented Roche acquisition agreement
Lund-anchored liquid biopsy MRD specialist with a named CEO, CLIA-certified US laboratory, commercial Pathlight Breast MRD test, and a disclosed 2026 Roche acquisition agreement worth up to 595 million USD.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
SAGA Diagnostics
Tumor-Informed Liquid Biopsy, Molecular Residual Disease Detection, and Cancer Monitoring · Clinical diagnostic service delivery
Lund-anchored liquid biopsy MRD specialist with a named CEO, CLIA-certified US laboratory, commercial Pathlight Breast MRD test, and a disclosed 2026 Roche acquisition agreement worth up to 595 million USD.
- Lead
- Peter Collins (verified ↗)
- Address
- Medicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical diagnostic service delivery
- Capabilities
- Whole-Genome Sequencing of Tumor Samples · Personalized Digital PCR ctDNA Panels · Blood-Based MRD Testing
- Founded
- 2014
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Peter Collins
Chief Executive Officer
Full addressMedicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Medicon Village member directory page listing SAGA Diagnostics at Scheelevagen 2.
Open sourceClinical diagnostic service delivery
Lund, Sweden. Tumor-Informed Liquid Biopsy, Molecular Residual Disease Detection, and Cancer Monitoring. Review completed on 24 Apr 2026.
Swedish Medical Products Agency and US CLIA oversight for the RTP laboratory
CLIA certification of the RTP laboratory, Public leadership disclosure, Documented Roche acquisition agreement
Tumor-Informed Liquid Biopsy, Molecular Residual Disease Detection, and Cancer Monitoring
Lund-anchored liquid biopsy MRD specialist with a named CEO, CLIA-certified US laboratory, commercial Pathlight Breast MRD test, and a disclosed 2026 Roche acquisition agreement worth up to 595 million USD.
Editorial note
SAGA Diagnostics combines a Medicon Village operating base with a CLIA-certified US laboratory and a disclosed Roche acquisition agreement (2026) that will fold the MRD platform into Foundation Medicine, making the Lund record an important 2026 MRD reference point.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Whole-Genome Sequencing of Tumor Samples
Personalized Digital PCR ctDNA Panels
Blood-Based MRD Testing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Whole-genome sequencers
Multiplex digital PCR platforms
Dual-site laboratory operations (Lund, Sweden and RTP, NC)
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is SAGA Diagnostics located?
- SAGA Diagnostics operates from Medicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden, Lund, Sweden.
- Who runs SAGA Diagnostics?
- SAGA Diagnostics is led by Peter Collins, Chief Executive Officer. Verified 24 Apr 2026.
- What does SAGA Diagnostics do?
- Lund-anchored liquid biopsy MRD specialist with a named CEO, CLIA-certified US laboratory, commercial Pathlight Breast MRD test, and a disclosed 2026 Roche acquisition agreement worth up to 595 million USD. Core capabilities: Whole-Genome Sequencing of Tumor Samples, Personalized Digital PCR ctDNA Panels, Blood-Based MRD Testing.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.